Heart Disease Trial, Recruiting NCT05800002 Sponsor: Nanjing First Hospital, Nanjing Medical University Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT05800002
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have silent ischemia (reduced blood flow to the heart with no symptoms), stable or unstable chest pain (angina), or have had a certain type of heart attack — either a non-ST-segment elevation heart attack more than 48 hours ago, or an ST-segment elevation heart attack more than 7 days ago
  • People who have a new blockage in a coronary artery (a blood vessel supplying the heart) that is suitable for treatment with a drug-coated stent (a small tube that holds the artery open and releases medication)
  • People whose blocked artery has heavy calcium buildup (hardening of the artery wall)

Who may not be able to join:

  • People under 18 years of age
  • People with a serious illness where life expectancy is expected to be less than 12 months
  • People who are unable to tolerate blood-thinning medications
  • People with significantly low red blood cell, platelet, or white blood cell counts (confirm with trial site)
  • People who have a history of major bleeding, such as bleeding in the brain or digestive system
  • People who have a completely blocked artery that could not be reopened
  • People who are planning to have a major surgery within the next 12 months
  • People whose heart pumping function is severely reduced (below 25%)
  • People with kidney failure who require regular dialysis
  • People who have previously had a drug-coated stent placed in the same artery being treated in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Shao-Liang Chen, MD, The First Affiliated Hospital with Nanjing Medical University

Phone: 025-52271350

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Nanjing First Hospital, Nanjing Medical University
Registry
ClinicalTrials.gov
Start date
7 April 2023
Est. completion
30 March 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

the rate of target-vessel failure at 12 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov